US Officials: Global Crises Require Accelerated Drug Evaluation
This article was originally published in Scrip
Executive Summary
With the world experiencing three major health crises in the past decade – severe acute respiratory syndrome, H1N1 pandemic influenza and Ebola – and the potential for other emerging diseases to turn into an epidemic, such as the Middle East respiratory syndrome coronavirus (MERS-CoV), there's a critical need for the rapid evaluation of experimental therapies, US officials said, laying out their argument in an Aug. 5 Perspectives article in the New England Journal of Medicine.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.